title: Cimetidine enhances the hepatoprotective action of N-acetylcysteine in mice treated with toxic doses of paracetamol.
abstract: Paracetamol, in toxic doses, is associated with extensive liver damage. This represents one of the common causes of morbidity and mortality in drug poisoning cases. This study was undertaken to investigate the possible potentiation of the hepatoprotective action of N-acetylcysteine (NAC) by cimetidine (CMD), an inhibitor of hepatic microsomal oxidative enzymes. The effects of NAC, cimetidine and the two in combination, administered 2 h post-paracetamol dose, on mortality, plasma glutamic oxaloacetic (GOT) and glutamic pyruvic (GPT) transaminase activities and hepatic reduced glutathione (GSH) levels were investigated in mice 24 h after treatment with a single oral dose of paracetamol (400 mg/kg). Both NAC and cimetidine caused a partial improvement of survival rate, plasma GOT and GPT activities. In addition, they prevented the depletion of hepatic GSH contents. However, concomitant administration of NAC and cimetidine produced a 100% survival rate and a marked reduction in plasma GOT and GPT activities to within the normal range, while significantly raising hepatic GSH concentrations to values close to those measured in saline-treated control animals. It is therefore concluded that cimetidine and N-acetylcysteine may have an additive hepatoprotective action in the treatment of paracetamol overdose.
authors.affiliation: Department of Pharmacology, College of Medicine and Medical Sciences, King Faisal University, Dammam, Saudi Arabia.
authors.forename: Z H
authors.initials: ZH
authors.lastname: Al-Mustafa
authors.forename: A K
authors.initials: AK
authors.lastname: Al-Ali
authors.forename: F S
authors.initials: FS
authors.lastname: Qaw
authors.forename: Z
authors.initials: Z
authors.lastname: Abdul-Cader
mesh_terms: D000082:Acetaminophen / Q000008:administration & dosage / Q000633:toxicity*; D000111:Acetylcysteine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000284:Administration, Oral; D000410:Alanine Transaminase / Q000097:blood; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000633:toxicity*; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D002927:Cimetidine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005978:Glutathione / Q000378:metabolism; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D008107:Liver Diseases / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D008297:Male; D051379:Mice; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D009336:Necrosis; D015996:Survival Rate
chemical_list: D018712:Analgesics, Non-Narcotic; D016166:Free Radical Scavengers; D006635:Histamine H2 Antagonists; D000082:Acetaminophen; D002927:Cimetidine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005978:Glutathione; D000111:Acetylcysteine